Lakeshore Biopharma Co, LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
20-F: LakeShore Biopharma Navigates Legal Challenges and R&D Shifts Amidst Mixed Fiscal 2025 Results
LakeShore Biopharma reported a narrowed net loss and increased revenue in fiscal year 2025, driven by strong rabies vaccine sales, but faces ongoing litigation, significant R&D shifts, and internal control weaknesses.
NASDAQ
LakeShore Biopharma details executive employment terms and compliance in recent SEC filings.